Alvesco

About Alvesco®

Alvesco® (ciclesonide) is an inhaled corticosteroid (ICS) for the treatment of persistent asthma in adults and adolescents (12 years and older). Alvesco® is administered as a prodrug and possesses a specific pharmacological profile. Mainly activated in the respiratory tract, Alvesco® controls the underlying cause of asthma – airway inflammation (Figure 1).

Read on for more information on asthma and asthma pathophysiology.

2 fig 1_Airway remodeling with ICS use
Figure 1: Alvesco® treats the underlying chronic inflammation associated with asthma

Formulated as a solution and delivered via a pressurized metered-dose inhaler (pMDI) using a hydrofluoroalkane (HFA) propellant, Alvesco® reaches both large and small airways.1 Alvesco® improves pulmonary function and reduces asthma symptoms, the number of exacerbations and the need for rescue medication.2,3 

For further information, visit the clinical efficacy section, and to discover which patients may benefit most from treating small airway inflammation with Alvesco®, please see the Patient profiles.

Two different Alvesco® inhalers are available: the Alvesco® 80 inhaler delivers 80 micrograms (µg) of ciclesonide with each actuation, and the Alvesco® 160 inhaler delivers 160µg of ciclesonide with each actuation (Figure 2).
 
2 fig 2_Alvesco inhalers
Figure 2: Two different Alvesco® inhalers are available

According to the EU summary of product characteristics (SmPC), the recommended dose of Alvesco® is 160µg once-daily, which leads to asthma control in the majority of patients. However, in severe asthmatics 320µg twice-daily (Figure 3) may be required to reduce the frequency of exacerbations, but without an improvement in lung function.4 Dose reduction to 80µg once-daily may be an effective maintenance dose for some patients. Once control is achieved, the dose of Alvesco® should be individualized and titrated to the minimum dose needed to maintain good asthma control.5
 
2 fig 3_Equipotent doses GINA
Figure 3: Estimated equipotent daily doses of inhaled glucocorticosteroids for adults (comparison based upon efficacy data)5 
Reproduced with permission from the Global Strategy for Asthma Management and Prevention 2012, © Global Initiative for Asthma (GINA) all rights reserved.


IMPORTANT NOTE:
Prescribing information varies from country to country according to the different requirements of local health regulatory authorities. Please ensure you consult your local prescribing information for full details.

Please find your local contact details from Takeda Worldwide database.


References

  1. Newman S, Salmon A, Nave R, et al. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006;100:375-84.
  2. Berger WE, Kerwin E, Bernstein DI, et al. Efficacy and safety evaluation of ciclesonide in subjects with mild-to-moderate asthma not currently using inhaled corticosteroids. Allergy Asthma Proc 2009;30:304-14.
  3. O'Connor BJ, Kilfeather S, Cheung D, et al. Efficacy and safety of ciclesonide in patients with severe asthma: a 12-week, double-blind, randomized, parallel-group study with long-term (1-year) follow-up. Expert Opin Pharmacother 2010;11:2791-803.
  4. Alvesco® EU SmPC. Date of last revision: November 2012.
  5. The Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention. Available from: http://www.ginasthma.org/. 2012
Loading ...